© 2008 Alexis Corporation
Viral Signalling
You are here: Product Lines > Viral Signalling
 
AG-AE0631 Revised 11-Jan-08
ACE2 (human) ELISA Kit
Add to Clipboard
SYNONYMS Angiotensin-converting Enzyme 2 (human) ELISA Kit
SARS Receptor (human) ELISA Kit
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Angiotensin Converting Enzyme [ACE] & ACE2 / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
AG-AE0631EK-KI01   96 wells 590.00 USD Add To Cart
AG-AE0631TP-KI01 Twin Plex 2x96 wells 890.00 USD Add To Cart
AG-AE0631PP-KI01 Penta Plex 5x96 wells 1'870.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
SENSITIVITY: 293pg/ml (range 0 to 50ng/ml)
APPLICATION: For the quantitative determination of ACE2 in human urine samples or cell culture supernatants.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: +4°C
Product Images
Please click on thumbnails to enlarge.
General Information
MANUFACTURER Manufactured by AdipoGen, Inc.
Further Categories Containing This Product:
SARS Coronavirus / Related Products • ELISA & EIA Kits
 
 
ALX-201-330 Revised 24-Jul-06
ACE2 (human):Fc (human) (recombinant)
Add to Clipboard
SYNONYMS Angiotensin-converting Enzyme 2 (human):Fc (human) (recombinant)
SARS Receptor (human):Fc (human) (recombinant)
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Angiotensin Converting Enzyme [ACE] & ACE2 / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-201-330-C050   50 µg 370.00 USD Add To Cart
Product Specification
SOURCE/HOST: Produced in HEK 293 cells. The signal peptide sequence and the extracellular domain of human ACE2 (angiotensin-converting enzyme 2) (aa 1-740) are fused at the C-terminus to the Fc portion of human IgG1.
CONCENTRATION: 1mg/ml
PURITY: ≥90% (SDS-PAGE)
FORMULATION: Liquid. 0.2µm-filtered solution in PBS.
ENDOTOXIN CONTENT: <0.1EU/µg protein (LAL test).
BIOLOGICAL ACTIVITY: Converts angiotensin I to angiotensin-(1-9).
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Working aliquots are stable for up to 3 months when stored at -20°C.
HANDLING: Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
Product Images
Please click on thumbnails to enlarge.
General Information
BACKGROUND/TECHNICAL INFORMATION

Swiss-Prot link Q9NRA7: Angiotensin converting enzyme-like protein (human)
MANUFACTURER Manufactured by Adipogen, Inc.
Further Categories Containing This Product:
Recombinant Proteins / Fusion Proteins • SARS Coronavirus / Related Products
 
 
ALX-201-356 Revised 18-Mar-08
ACE2, Soluble (human) (recombinant)
Add to Clipboard
SYNONYMS Angiotensin-converting Enzyme 2, Soluble (human) (recombinant)
SARS Receptor, Soluble (human) (recombinant)
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Angiotensin Converting Enzyme [ACE] & ACE2 / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-201-356-C010   10 µg 295.00 USD Add To Cart
ALX-201-356-C050   50 µg 795.00 USD Add To Cart
Product Specification
EC: 3.4.17.-
SOURCE/HOST: Produced in HEK 293 cells. The signal peptide sequence and the extracellular domain of human ACE2 (angiotensin-converting enzyme 2) (aa 1-740) are fused at the C-terminus to a FLAG®-tag.
CONCENTRATION: 1mg/ml
PURITY: ≥90% (SDS-PAGE)
FORMULATION: Liquid. 0.2µm-filtered solution in PBS.
ENDOTOXIN CONTENT: <0.1EU/µg protein (LAL-test).
BIOLOGICAL ACTIVITY: Converts angiotensin I to angiotensin-(1-9).
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Working aliquots are stable for up to 3 months when stored at -20°C.
HANDLING: After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Product Images
Please click on thumbnails to enlarge.
General Information
BACKGROUND/TECHNICAL INFORMATION Swiss-Prot link Q9NRA7: Angiotensin converting enzyme-like protein (human)

FLAG is a registered trademark of Sigma-Aldrich Co.
MANUFACTURER Manufactured by AdipoGen, Inc.
Further Categories Containing This Product:
Recombinant Proteins / Fusion Proteins • SARS Coronavirus / Related Products
 
 
ALX-350-325 Revised 25-Jun-07
Altenusin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - Antifungal
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-325-M001   1 mg 110.00 USD Add To Cart
ALX-350-325-M005   5 mg 380.00 USD Add To Cart
Product Specification
FORMULA: C15H14O6
MW: 290.3
CAS NUMBER: 31186-12-6
SOURCE/HOST: Isolated from Alternaria sp.
PURITY: ≥97% (HPLC)
APPEARANCE: Yellow to brown solid.
SOLUBILITY: Soluble in DMSO or 100% ethanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.
IDENTITY: Identity determined by 1H-NMR, 13C-NMR and MS.

Product Description
Antifungal penicillide. Non-competitive, specific neutral sphingomyelinase (N-SMase) and strong pp60c-Src inhibitor. Inhibits cFMS receptor tyrosine kinase (CSF-1/m-CSF receptor tyrosine kinase) which is implicated in cancer and bone diseases. Myosin light chain kinase inhibitor. Exhibits anti-HIV-1 integrase activity.
Product Specific Literature References
Studies in the biochemistry of micro-organisms. 103. Metabolites of Alternaria tenuis Auct.: Culture filtrate products: T. Rosett, et al.; Biochem. J. 67, 390 (1957) Full Text
Studies in the biosynthesis of fungal metabolites. 4. Alternariol monomethyl ether and its relation to other phenolic metabolites of Alternaria tenuis: R. Thomas; Biochem. J. 80, 234 (1961) Abstract; Full Text
Metabolites of some Alternaria species. The structures of altenusin and dehydroaltenusin: R. G. Coombe, et al.; Aus. J. Chem. 23, 2343 (1970)
Host-specific toxins and chemical structures from alternaria species: S. Nishimura, et al.; Ann. Rev. Phytopathol. 21, 87 (1983)
The metabolites of Talaromycesflavus: Part 1. Metabolites of the organic extracts : W. A. Ayer, et al.; Can. J. Chem. 68, 2085 (1990)
Isolation of myosin light chain kinase inhibitors from microorganisms: dehydroaltenusin, altenusin, atrovenetinone, and cyclooctasulfur: S. Nakanishi, et al.; Biosci. Biotechnol. Biochem. 59, 1333 (1995) Abstract
Alutenusin, a specific neutral sphingomyelinase inhibitor, produced by Penicillium sp. FO-7436: R. Uchida, et al.; J. Antibiot. 52, 572 (1999) Abstract
Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolites: S.B. Singh, et al.; J. Ind. Microbiol. Biotechnol. 30, 721 (2003) Abstract
Fungal metabolites as potent protein kinase inhibitors: Identification of a novel metabolite and novel activities of known metabolites : M. Oyama, et al.; Lett. Drug Design Discov. 1, 24 (2004)
New penicillide derivatives isolated from Penicillium simplicissimum: S. I. Komai, et al.; J. Nat. Med. 60, 185 (2006)
HIV-1 integrase inhibitors: 2003-2004 update: R. Dayam, et al.; Med. Res. Rev. 26, 271 (2006) Abstract
Further Categories Containing This Product:
Tyrosine Kinase Inhibitors • Myosin Light Chain Kinase Inhibitors • Antibiotics - Antiviral / Anti-HIV
 
 
ALX-350-312 Revised 28-May-08
(-)-Arctigenin
Add to Clipboard
SYNONYMS (3R,4R)-4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2-(3H)-furanone
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Antitumor Reagents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-312-M025   25 mg 70.00 USD Add To Cart
Product Specification
FORMULA: C21H24O6
MW: 372.4
CAS NUMBER: 7770-78-7
SOURCE/HOST: Isolated from Arctium lappa.
PURITY: ≥97% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO (34mg/ml, heating, sonication); sparingly soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Lignan derivative, which shows antitumor, anti-inflammatory, immunomodulatory and neuroprotective activities. Down-regulates anti-apoptotic protein Bcl-XL. Potent inhibitor of HIV type-I integrase and DNA topoisomerase II. Shows phytoestrogenic and cytotoxic properties against Hep62 cells.  Antagonist for platelet activating factor and Ca2+. Blocks the activation of Akt (protein kinase B; PKB) induced by glucose starvation.
Product Specific Literature References
Antiproliferative effect of Arctigenin and Arctiin: S.Y. Ryu, et al.; Arch. Pharm. Res. 18, 462 (1995)
(-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase: E. Eich, et al.; J. Med. Chem 39, 86 (1996) Abstract
Immunomodulatory effect of arctigenin, a lignan compound, on tumour necrosis factor-alpha and nitric oxide production, and lymphocyte proliferation: J.Y. Cho, et al.; J. Pharm. Pharmacol. 51, 1267 (1999) Abstract
Arctigenin protects cultured cortical neurons from glutamate-induced neurodegeneration by binding to kainate receptor: Y.P. Jang, et al.; J. Neurosci. Res. 68, 233 (2002) 68, 233 (2002) Abstract
A phytochemical study of lignans in whole plants and cell suspension cultures of Anthriscus sylvestris: A. Koulman, et al.; Planta Med. 69, 733 (2003) Abstract
Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells: B. Hausott, et al.; J. Cancer Res. Clin. Oncol. 129, 569 (2003) Abstract
Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: the role in TNF-alpha inhibition: M.K. Cho, et al.; Int. Immunopharmacol. 4, 1419 (2004) Abstract
Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: the role in TNF-alpha inhibition: M.K. Cho, et al.; Int. Immunopharmacol. 4, 1419 (2004) Abstract
Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation: S. Awale, et al.; Cancer Res. 66, 1751 (2006) Abstract
The chemopreventive effects of Saussurea salicifolia through induction of apoptosis and phase II detoxification enzyme: K. Kang, et al.; Biol. Pharm. Bull. 30, 2352 (2007) Abstract
Further Categories Containing This Product:
Bcl-2 Family Modulators • Natural Products - Nitric Oxide Pathway Modulators • Platelet Activating Factors [PAF] & Receptors / Related Products • Natural Products - Topoisomerase Inhibitors • Natural Products - Immunomodulators • Natural Products - Anti-inflammatory Agents • Natural Products - Antiviral / anti-HIV Agents • HIV / AIDS / Related Products
 
 
ALX-350-318 Revised 17-Jun-08
(-)-Arctiin
Add to Clipboard
SYNONYMS (3R,4R)-4-[(3,4-Dimethoxyphenyl)methyl]-3-[[4-(β-D-glucopyranosyloxy)-3-methoxyphenyl]methyl]dihydro-2(3H)-furanone
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Antitumor Reagents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-318-M025   25 mg 60.00 USD Add To Cart
Product Specification
FORMULA: C27H34O11
MW: 534.6
CAS NUMBER: 20362-31-6
SOURCE/HOST: Isolated from Arctium lappa.
PURITY: ≥95% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO (5mg/ml); sparingly soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.

Product Description

Lignan derivative with antitumor activities. Down-regulates anti-apoptotic protein Bcl-XL. Potent inhibitor of HIV type-I integrase and DNA topoisomerase II. Shows phytoestrogenic activity and is an antagonist for platelet activating factor and Ca2+.
Product Specific Literature References
Platelet activating factor (PAF) antagonists contained in medicinal plants: lignans and sesquiterpenes: S. Iwakami, et al.; Chem. Pharm. Bull. (Tokyo) 40, 1196 (1992) Abstract
Antiproliferative effect of Arctigenin and Arctiin: S.Y. Ryu, et al.; Arch. Pharm. Res. 18, 462 (1995)
Cytotoxic components of bardanae fructus (goboshi): S. Moritani, et al.; Biol. Pharm. Bull. 19, 1515 (1996) Abstract
Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection: A.J. Vlietinck, et al.; Planta Med. 64, 97 (1998) Abstract
Anti-tumor-promoting activity of lignans from the aerial part of Saussurea medusa: M. Takasaki, et al.; Cancer Lett. 158, 53 (2000) Abstract
Isolation and identification of arctiin and arctigenin in leaves of burdock (Arctium lappa L.) by polyamide column chromatography in combination with HPLC-ESI/MS: S. Liu, et al.; Phytochem. Anal. 16, 86 (2005) Abstract
Application of preparative high-speed counter-current chromatography for separation and purification of arctiin from Fructus Arctii: X. Wang, et al.; J. Chromatogr. A. 1063, 247 (2005) Abstract
The chemopreventive effects of Saussurea salicifolia through induction of apoptosis and phase II detoxification enzyme: K. Kang, et al.; Biol. Pharm. Bull. 30, 2352 (2007) Abstract
Further Categories Containing This Product:
Antitumor Agents (Anti-proliferative) • Bcl-2 Family Modulators • Platelet Activating Factors [PAF] & Receptors / Related Products • Natural Products - Immunomodulators • Natural Products - Topoisomerase Inhibitors • Natural Products - Antiviral / anti-HIV Agents • HIV / AIDS / Related Products
 
 
ALX-350-375 Revised 22-Jul-08 New product
Arcyriaflavin A
Add to Clipboard
PRODUCT LINE Cell Cycle
PRODUCT CATEGORY CDK & Cyclin Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-375-M001   1 mg 160.00 USD Add To Cart
Product Specification
FORMULA: C20H11N3O2
MW: 325.3
CAS NUMBER: 118458-54-1
SOURCE/HOST: Synthetic. Originally isolated from the marine ascidian Eudistoma sp.
PURITY: ≥95% (HPLC)
APPEARANCE: Orange to red solid.
SOLUBILITY: Soluble in DMSO (50mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stock solutions are stable for up to 3 months at -20°C.
HANDLING: After reconstitution, prepare aliquots and store at -20°C. Protect from light. Packaged under inert gas.

Product Description
Potent inhibitor of CDK4 / cyclin D1 (IC50 = 59nM). Inhibits human cytomegalovirus (HCMV) replication in cell culture (IC50 = 200nM).
Product Specific Literature References
Staurosporine aglycone (K252-c) and arcyriaflavin A from the marine ascidian, Eudistoma sp: P.A. Horton, et al.; Experientia 50, 843 (1994) Abstract
Indolocarbazoles: potent, selective inhibitors of human cytomegalovirus replication: M.J. Slater, et al.; Bioorg. Med. Chem. 7, 1067 (1999) Abstract
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors: C. Sanchez-Martinez, et al.; Bioorg. Med. Chem. Lett. 13, 3835 (2003) Abstract
Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors: G. Zhu, et al.; Bioorg. Med. Chem. Lett. 13, 1231 (2003) Abstract
Two indolocarbazole alkaloids with apoptosis activity from a marine-derived actinomycete Z(2)039-2: R. Liu, et al.; Arch. Pharm. Res. 30, 270 (2007) Abstract
Further Categories Containing This Product:
Natural Products for Cell Cycle Research • Antiviral Agents Other Products
 
 
ALX-350-334 Revised 03-Apr-08
Ascochlorin
Add to Clipboard
SYNONYMS LL-Z 1272 γ
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antitumor Antibiotics
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-334-MC05   0.5 mg 320.00 USD Add To Cart
Product Specification
FORMULA: C23H29ClO4
MW: 404.9
CAS NUMBER: 26166-39-2
RTECS: VH3707560
SOURCE/HOST: Isolated from Acremonium sp. MST-FP1890.
PURITY: ≥95% (HPLC)
APPEARANCE: White to light grey powder.
SOLUBILITY: Soluble in 100% ethanol, methanol, dimethyl formamide or DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.
HAZARD: TOXIC.

Product Description
Antitumor antibiotic. Shows antiviral activity. Inhibitor or matrix metalloproteinase 9 (MMP-9). Reduces the inflammatory response to TNF-α in rat vascular smooth muscle cells. May be useful as an antiatherogenic agent.
Product Specific Literature References
Ascochlorin, a new antibiotic, found by the paper-disc agar-diffusion method. I. Isolation, biological and chemical properties of ascochlorin. (Studies on antiviral and antitumor antibiotics. I): G. Tamura, et al.; J. Antibiot. (Tokyo) 21, 539 (1968) Abstract
Ascochlorin derivatives as ligands for nuclear hormone receptors: M. Togashi, et al.; J. Med. Chem. 46, 4113 (2003) Abstract
Ascochlorin inhibits matrix metalloproteinase-9 expression by suppressing activator protein-1-mediated gene expression through the ERK1/2 signaling pathway: inhibitory effects of ascochlorin on the invasion of renal carcinoma cells: S. Hong, et al.; J. Biol. Chem. 280, 25202 (2005) Abstract; Full Text
Selective cytotoxicity of ascochlorin in ER-negative human breast cancer cell lines: K. Sakaguchi, et al.; BBRC 329, 46 (2005) Abstract
Ascochlorin suppresses oxLDL-induced MMP-9 expression by inhibiting the MEK/ERK signaling pathway in human THP-1 macrophages: J.H. Kang, et al.; J. Cell. Biochem. 102, 506 (2007) Abstract
Further Categories Containing This Product:
MMP Inhibitors • Antibiotics for Cytoskeletal Research • Antibiotics for Inflammation Research • Antibiotics - Antiviral / Anti-HIV
 
 
ALX-350-319 Revised 03-Apr-08
Avarol
Add to Clipboard
SYNONYMS NSC306951
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Chemopreventive Agents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-319-M001   1 mg 185.00 USD Add To Cart
Product Specification
FORMULA: C21H30O2
MW: 314.5
CAS NUMBER: 55303-98-5
SOURCE/HOST: Isolated from marine sponge Dysidea avara.
PURITY: ≥97% (HPLC)
APPEARANCE: Brown solid.
SOLUBILITY: Soluble in DMSO or 100% ethanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.
IDENTITY: Determined by 1H-NMR, 13C-NMR and MS.

Product Description
Cytostatic agent which has potent antileukemic activity both in vitro and in vivo (mice). Also displays antibacterial and antifungal activities against a limited range of microorganisms. Inhibits HIV-1 reverse transcriptase.
Product Specific Literature References
Antimicrobial activity of avarol, a sesquiterpenoid hydroquinone from the marine sponge, Dysidea avara: L. Cariello, et al.; Comp. Biochem. Physiol. 71, 281 (1982) Abstract
Antimutagenic activity of the novel antileukemic agents, avarone and avarol: B. Kurelec, et al.; Mutat. Res. 144, 63 (1985) Abstract
Potent antileukemic activity of the novel cytostatic agent avarone and its analogues in vitro and in vivo: W.E. Muller, et al.; Cancer Res. 45, 4822 (1985) Abstract
Inhibition of mitosis by avarol, a natural product isolated from the sponge Dysidea avara: W.E. Muller, et al.; Basic Appl. Histochem. 29, 321 (1985) Abstract
Biphasic and differential effects of the cytostatic agents avarone and avarol on DNA metabolism of human and murine T and B lymphocytes: W.E. Muller, et al.; Eur. J. Cancer Clin. Oncol. 22, 473 (1986) Abstract
Avarol-induced DNA strand breakage in vitro and in Friend erythroleukemia cells: W.E. Muller, et al.; Cancer Res. 47, 6565 (1987) Abstract
Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone: P.S. Sarin, et al.; J. Natl. Cancer Inst. 78, 663 (1987) Abstract
Action of the antileukemic and anti-HTLV-III (anti-HIV) agent avarol on the levels of superoxide dismutases and glutathione peroxidase activities in L5178y mouse lymphoma cells: E. Batke, et al.; Cell Biochem. Funct. 6, 123 (1988) Abstract
Induction of gamma-interferon by avarol in human peripheral blood lymphocytes: R. Voth, et al.; Jpn. J. Cancer Res. 79, 647 (1988) Abstract
Suppression of the modulatory effects of the antileukemic and anti-human immunodeficiency virus compound avarol on gene expression by tryptophan: H.C. Schroder, et al.; Cancer Res. 49, 2069 (1989) Abstract
The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives: S. Loya and A. Hizi; FEBS Lett. 269, 131 (1990) Abstract; Full Text
Avarol restores the altered prostaglandin and leukotriene metabolism in monocytes infected with human immunodeficiency virus type 1: H.C. Schroder, et al.; Virus Res. 21, 213 (1991) Abstract
Effect of avarol and avarone on in vitro-induced microsomal lipid peroxidation: M.A. Belisario, et al.; Toxicology 72, 221 (1992) Abstract
Avarol and avarone, two new anti-inflammatory agents of marine origin: M.L. Ferrandiz, et al.; Eur. J. Pharmacol. 253, 75 (1994) Abstract
In vitro effect of avarone and avarol, a quinone/hydroquinone couple of marine origin, on platelet aggregation: M.A. Belisario, et al.; Pharmacol. Toxicol. 79, 300 (1996) Abstract
Application of cell culture for the production of bioactive compounds from sponges: synthesis of avarol by primmorphs from Dysidea avara: W.E. Muller, et al.; J. Nat. Prod. 63, 1077 (2000) Abstract
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line: M. Amigo, et al.; J. Nat. Prod. 67, 1459 (2004) Abstract
Sustainable production of bioactive compounds by sponges--cell culture and gene cluster approach: a review: W.E. Muller, et al.; Mar. Biotechnol. (NY) 6, 105 (2004) Abstract
Reactivity and biological activity of the marine sesquiterpene hydroquinone avarol and related compounds from sponges of the order Dictyoceratida: D. Sladic & M.J. Gasic; Molecules 11, 1 (2006) Abstract
Evaluation of the activity of the sponge metabolites avarol and avarone and their synthetic derivatives against fouling micro- and macroorganisms: M. Tsoukatou, et al.; Molecules 12, 1022 (2007) Abstract
Further Categories Containing This Product:
Natural Products - Immunomodulators • Natural Products - Antiviral / anti-HIV Agents • Natural Products with Antibiotic Activity • HIV / AIDS / Related Products
 
 
ALX-350-321 Revised 20-Dec-07
Avarone
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Chemopreventive Agents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-321-M001   1 mg 185.00 USD Add To Cart
Product Specification
FORMULA: C21H28O2
MW: 312.5
CAS NUMBER: 55303-99-6
SOURCE/HOST: Isolated from marine sponge Dysidea avara.
PURITY: ≥97% (HPLC)
APPEARANCE: Brown oil.
SOLUBILITY: Soluble in DMSO or 100% ethanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.
IDENTITY: Determined by 1H-NMR, 13C-NMR and MS.

Product Description
Cytostatic agent which has potent antileukemic activity both in vitro and in vivo (mice). Also displays antibacterial and antifungal activities against a limited range of microorganisms.
Product Specific Literature References
Antimutagenic activity of the novel antileukemic agents, avarone and avarol: B. Kurelec, et al.; Mutat. Res. 144, 63 (1985) Abstract
Potent antileukemic activity of the novel cytostatic agent avarone and its analogues in vitro and in vivo: W.E. Muller, et al.; Cancer Res. 45, 4822 (1985) Abstract
Biphasic and differential effects of the cytostatic agents avarone and avarol on DNA metabolism of human and murine T and B lymphocytes: W.E. Muller, et al.; Eur. J. Cancer Clin. Oncol. 22, 473 (1986) Abstract
Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone: P.S. Sarin, et al.; J. Natl. Cancer Inst. 78, 663 (1987) Abstract
Suppression of the modulatory effects of the antileukemic and anti-human immunodeficiency virus compound avarol on gene expression by tryptophan: H.C. Schroder, et al.; Cancer Res. 49, 2069 (1989) Abstract
The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives: S. Loya and A. Hizi; FEBS Lett. 269, 131 (1990) Abstract; Full Text
Effect of avarol and avarone on in vitro-induced microsomal lipid peroxidation: M.A. Belisario, et al.; Toxicology 72, 221 (1992) Abstract
Avarol and avarone, two new anti-inflammatory agents of marine origin: M.L. Ferrandiz, et al.; Eur. J. Pharmacol. 253, 75 (1994) Abstract
In vitro effect of avarone and avarol, a quinone/hydroquinone couple of marine origin, on platelet aggregation: M.A. Belisario, et al.; Pharmacol. Toxicol. 79, 300 (1996) Abstract
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line: M. Amigo, et al.; J. Nat. Prod. 67, 1459 (2004) Abstract
Sustainable production of bioactive compounds by sponges--cell culture and gene cluster approach: a review: W.E. Muller, et al.; Mar. Biotechnol. (NY) 6, 105 (2004) Abstract
Protein covalent modification by biologically active quinones: D. Sladic, et al.; J. Serb. Chem. Soc. 69, 9